Italfarmaco is a multinational pharmaceutical company dedicated to advancing healthcare through innovative research and development. The company focuses on creating effective treatments, particularly for rare diseases, and emphasizes the importance of accessibility in healthcare. Italfarmaco operates four research hubs where it develops new dosing solutions, repurposes existing formulations, and creates active pharmaceutical ingredients (APIs) to enhance the availability of high-quality generic medicines. Their commitment to pharmaceutical innovation is evident in their ongoing projects, which include the development of small molecules, peptides, and monoclonal antibodies, particularly targeting histone deacetylase (HDAC) inhibitors for conditions such as Duchenne Muscular Dystrophy and Polycythemia Vera.

The company's research and development efforts are structured into specialized units that streamline the process from drug discovery to market approval. This includes the New Drug Incubator (NDI) for identifying new chemical entities and the Drug Development (DD) unit for advancing candidates through clinical trials. Italfarmaco's R&D is characterized by a collaborative approach, leveraging both internal expertise and external partnerships to drive innovation. Their focus on epigenetics and the HDAC family of enzymes highlights their commitment to addressing complex medical challenges, while their production facilities ensure that they maintain high standards of quality and safety in their pharmaceutical offerings.

Spain

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries.
The company was founded in Milan in 1938.
The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros.

Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.

Italfarmaco

Company Details